伊立替康联合奥沙利铂治疗晚期复发转移卵巢癌的临床观察

Irinotecan Combined with Oxaliplatin in the Treatment of Relapse or Metastatic Ovarian Cancer

目的观察伊立替康联合奥沙利铂治疗晚期复发转移卵巢癌的疗效及毒副反应。方法 34例晚期复发转移卵巢癌患者予以伊立替康联合奥沙利铂治疗。结果 34例晚期复发转移卵巢癌患者中,CR 8例,PR 11例,SD 12例,PD 4例,总有效率55.9%。中位肿瘤进展时间为6.8个月。毒副反应主要为骨髓抑制、胃肠道反应和神经毒性,均经对症处理后缓解或自行缓解。结论伊立替康联合奥沙利铂治疗晚期复发转移卵巢癌疗效确切,毒副反应可耐受。

Objective To research the effectiveness and toxicities of irinotecan combined with oxaliplatin in the treatment of relapse or metastatic ovarian cancer. Methods Thirty-four patients with relapse or metastatic ovarian cancer were treated with irin0tecan combined with oxaliplatin. Results Of the 34 patient^with relapse or metastatic o- varian cancer, CR was observed in the 8 patients, PR in the 11 patients, SD in the 12 patients, PD in the 4 patients, the response rate was 55.9%. The median time to progression was 6.8 months. The main toxicities were myelosuppression, gastrointestinal reaction and neurotoxicity. Conclusion Irinotecan combined with oxaliplatin is effective and safe in the treatment of relapse or metastatic ovarian cancer.